Serum levels of biomarkers at baseline comparing patients with systemic JIA (n=10) versus non-systemic JIA (n=226)
| All | Systemic JIA (sJIA) | Non-systemic JIA (non-sJIA) | P value sJIA versus non-sJIA | |
| n | 236 | 10 | 226 | |
| IL-1β | 16.5 (6.7–30.5) | 19.2 (11.6–32.1) | 16.5 (6.2–30.5) | 0.462 |
| IL-4 | 88.6 (55.4–132.7) | 94 (5–191) | 89 (57–133) | 0.951 |
| IL-6 | 6.7 (3.2–13.0) | 11.5 (3.6–46.0) | 6.7 (3.2–12.6) | 0.254 |
| IL-10 | 5.3 (2.3–7.1) | 6.7 (2.7–10.5) | 5.3 (2.3–7.1) | 0.180 |
| IL-12p70 | 13.4 (0.5–72.5) | 31.2 (0.5–108.4) | 13.4 (0.5–72.5) | 0.524 |
| IL-13 | 497 (387–621) | 576 (461–719) | 497 (387–621) | 0.080 |
| IL-17 | 10.3 (0.8–16.2) | 16.7 (5.2–36.1) | 9.7 (0.8–16.0) | 0.161 |
| IL-18 | 205 (136–291) | 2377 (594–8409) | 198 (136–273) | <0.001** |
| TNFα | 9.2 (1.7–16.6) | 6.7 (1.0–27.3) | 9.2 (22–16.6) | 0.932 |
| MMP-3 | 5174 (1747–17 493) | 12 368 (2706–65 192) | 5064 (1727–16 424) | 0.172 |
| CCL-2 | 180 (112–251) | 135 (49–172) | 183 (112–255) | 0.102 |
| sCD25 | 587 (420–766) | 709 (427–891) | 581 (418–760) | 0.394 |
| GM-CSF | 0.4 (0.4–3.8) | 3.2 (0.4–13.5) | 0.4 (0.4–3.7) | 0.059 |
| MPO | 2294 (1579–3572) | 2367 (1953–5161) | 2289 (1533–3565) | 0.449 |
| S100A9 | 511 (314–1277) | 2786 (949–5643) | 505 (309–1054) | 0.006* |
| S100A12 | 924 (434–1610) | 1947 (1253–10 124) | 904 (431–1601) | 0.007* |
Values are in picograms/millilitre (pg/mL) expressed as median (IQR). *P<0.01; **p<0.001.
CCL-2, chemokine ligand 2; GM-CSF, granulocyte-macrophage colony-stimulating factor; IL, interleukin; JIA, juvenile idiopathic arthritis; MMP-3, matrix metalloproteinase 3; MPO, myeloperoxidase; S100A9, S100 calcium-binding protein A9; S100A12, S100 calcium-binding protein A12; sCD25, soluble CD25; TNFα, tumour necrosis factor alpha.